Scientific Advisors
- Charles T. Campbell PhD – University of Washington
- Leroy Hood – Institute for Systems Biology
- Joshua LaBaer – Biodesign Institute at Arizona State University
- James Richey – Richey and Associates
- Ulf Jönsson – Retired
- Craig Beeson – Medical University of South Carolina
Professor Charles T. Campbell PhD
Charlie Campbell is Professor of Chemistry and Adjunct Professor of Physics and Chemical Engineering at the University of Washington, Seattle, WA, and Editor-in-Chief of the journal, Surface Science. He has served as the Director of the University of Washington’ Center for Nanotechnology (2003-4).
His numerous awards include the Lloyd E. and Florence M. West Endowed Professorship in Chemistry, the Alexander von Humboldt Research Award (2003), the American Chemical Society Colloid and Surface Chemistry Award (2001), and the Overseas Visiting Scholar Fellowship (1996) at St. John’ College, Cambridge University, England.
He has served as Chairman, Vice Chairman and Treasurer of the Colloid and Surface Chemistry Division of the American Chemical Society, as National President and Vice President of Phi Lambda Upsilon, Honorary Chemical Society, and on the Editorial Boards of the Journal of Chemical Physics and the Journal of Catalysis.
He has a B.S. in Chemical Engineering from the University of Texas at Austin and a Ph.D. in Physical Chemistry from the University of Texas at Austin.
Professor Leroy Hood
Leroy Hood, M.D., Ph.D. is recognized as one of the world’s leading scientists in molecular biotechnology and genomics, holding numerous patents and awards for his scientific breakthroughs. Dr. Hood earned an M.D. from Johns Hopkins University in 1964 and a Ph.D. in biochemistry from the California Institute of Technology in 1968. Since then, his research has focused on the study of molecular immunology and biotechnology. He has published more than 600 peer-reviewed papers and co-authored textbooks in biochemistry, immunology, molecular biology and genetics.
His professional career began at Caltech, where he and colleagues pioneered four instruments, the DNA and protein synthesizers and sequencers that constitute the technological foundation for contemporary molecular biology. One of the instruments has revolutionized genomics by allowing the rapid automated sequencing of DNA. Dr. Hood also was one of the first advocates and is a key player in the Human Genome Project — the quest to decipher the sequence of human DNA.
In 2000, Dr. Hood founded the Institute for Systems Biology in Seattle, Washington to pioneer systems approaches to biology and medicine. He is president and director of this organization and continues with his interest in biology, medicine, technology development, and computational biology
Dr. Hood has played a role in founding several biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin, Rosetta, and MacroGenics. His numerous awards include the Kyoto Prize for Advanced Technology (2002).
Professor Joshua LaBaer
Joshua LaBaer, MD, PhD, is the newly appointed director of the Virginia G. Piper Center for Personalized Diagnostics with in the Biodesign Institute at Arizona State University. He was also the founder and Director of the Institute of Proteomics at Harvard Medical School, and is a board certified oncologist in Massachusetts. He attended the University of California at Berkeley as an undergraduate and completed medical school and graduate school at the University of California, San Francisco, where he studied steroid regulation of DNA transcription and protein-DNA interactions.
He completed his clinical studies at the Brigham and Women’s Hospital and a clinical fellowship in Oncology at the Dana-Farber Cancer Institute in Boston. He also pursued research interests at the Massachusetts General Hospital in Boston in the areas of breast cancer, mammalian cell cycle regulation and cell cycle checkpoint genes.
Dr. LaBaer is the inventor of a new protein array technology called Nucleic Acid Programmable Protein Arrays (NAPPA). The NAPPA technology, first published in the July 2004 issue of the journal Science, provides a simple, cost-effective way to produce, as a single element of a microarray, freshly synthesized protein corresponding to any gene of known sequence.
He currently holds an academic appointment through the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. The author of numerous publications, Dr. LaBaer is also an associate editor of the Journal of Proteome Research, a member of the Scientific Advisory Committee for the Proteome Society and a founding member of the Human Proteome Organization.
Jim Richey
Mr. Richey is a co-founder, President and CEO of Auguron, a protein array company spun out of Harvard Medical School. Mr. Richey has been involved with a variety of biotech tool companies in varying and increasing levels of responsibility for the last 30 years. Companies in which he has held the position of Vice President or above include: Pharmacia, Biacore, PerSeptive, Applied Biosystems, LJL biosystems, Molecular Devices, and DiscoveRx. For the last 5 years Mr. Richey has run a successful consulting practice devoted to supporting the tool company space.
Ulf Jönsson, Ph.D.
Dr. Ulf Jönsson has a distinguished career spanning more than 20 years as an executive in the life science supply industry. Most notably, he was one of the three founders of Biacore AB, which began in 1984 as a research department within Pharmacia Fine Chemicals. In 1987 this research was transferred into a wholly owned subsidiary, Pharmacia Biosensor AB, which became Biacore AB in 1996. Biacore was subsequently acquired by GE Healthcare in 2006. Dr. Jönsson was CEO at Biacore from 2000 until 2004. He holds a Ph.D. in applied physics from the University of Linköping in Sweden.
Craig Beeson, Ph.D.
Craig Beeson comes from Southern California where he obtained his Ph.D. in synthetic and physical organic chemistry from the University of California at Irvine. He continued his studies with postdoctoral research under the supervision of Harden McConnell at Stanford University where he studied biophysics and immunology. He started his academic career at the University of Washington in Seattle in the Departments of Chemistry, Biochemistry, and Immunology. He was recruited to the Department of Pharmaceutical and Biomedical Sciences at the Medical University of South Carolina in 2002 where he remains today. The focus of his research is in the areas of structure-based drug design, analyses of signaling networks, and the regulation of cellular energy metabolism. He is the director of the MUSC Metabolomics Core and the MUSC Drug Design and Synthesis Core.